Trial Outcomes & Findings for Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 (NCT NCT00577577)

NCT ID: NCT00577577

Last Updated: 2022-01-06

Results Overview

The 6MWT measured the distance in meters that participants were able to walk over a total of six minutes. After a 10 minute resting period, the participants completed the 6MWT on a hard, flat surface at baseline and at Week 24.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

69 participants

Primary outcome timeframe

Baseline and Week 24

Results posted on

2022-01-06

Participant Flow

Participants were enrolled at 13 research centers in the United States from December 2007 to December 2008.

Participants were randomized in a 1:1 ratio to receive either IPLEX™ (Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 \[rhIGF-I/rhIGFBP-3\]) or matched placebo for 24 weeks.

Participant milestones

Participant milestones
Measure
IPLEX™
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Overall Study
STARTED
34
35
Overall Study
Received Treatment
34
35
Overall Study
COMPLETED
29
30
Overall Study
NOT COMPLETED
5
5

Reasons for withdrawal

Reasons for withdrawal
Measure
IPLEX™
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Overall Study
Adverse Event
3
2
Overall Study
Lost to Follow-up
1
0
Overall Study
Protocol Violation
0
3
Overall Study
Transportation
1
0

Baseline Characteristics

Ethnicity was not collected.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
IPLEX™
n=34 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=35 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Total
n=69 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
34 Participants
n=99 Participants
35 Participants
n=107 Participants
69 Participants
n=206 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Continuous
46.36 Years
STANDARD_DEVIATION 8.74 • n=99 Participants
44.17 Years
STANDARD_DEVIATION 10.40 • n=107 Participants
45.25 Years
STANDARD_DEVIATION 9.62 • n=206 Participants
Sex: Female, Male
Female
16 Participants
n=99 Participants
19 Participants
n=107 Participants
35 Participants
n=206 Participants
Sex: Female, Male
Male
18 Participants
n=99 Participants
16 Participants
n=107 Participants
34 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=99 Participants • Ethnicity was not collected.
2 Participants
n=107 Participants • Ethnicity was not collected.
3 Participants
n=206 Participants • Ethnicity was not collected.
Ethnicity (NIH/OMB)
Not Hispanic or Latino
33 Participants
n=99 Participants • Ethnicity was not collected.
33 Participants
n=107 Participants • Ethnicity was not collected.
66 Participants
n=206 Participants • Ethnicity was not collected.
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants • Ethnicity was not collected.
0 Participants
n=107 Participants • Ethnicity was not collected.
0 Participants
n=206 Participants • Ethnicity was not collected.
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
Race (NIH/OMB)
White
30 Participants
n=99 Participants
33 Participants
n=107 Participants
63 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=99 Participants
1 Participants
n=107 Participants
3 Participants
n=206 Participants
Region of Enrollment
United States
34 participants
n=99 Participants
35 participants
n=107 Participants
69 participants
n=206 Participants

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

The 6MWT measured the distance in meters that participants were able to walk over a total of six minutes. After a 10 minute resting period, the participants completed the 6MWT on a hard, flat surface at baseline and at Week 24.

Outcome measures

Outcome measures
Measure
IPLEX™
n=25 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=27 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline to Week 24 in Distance Walked as Assessed by the Six-minute Walk Test (6MWT) Distance
12.40 meters
Standard Deviation 44.75
20.11 meters
Standard Deviation 50.87

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

The number of steps taken per day was measured using a step activity monitor for 7 days at baseline and again at Week 24. Change from baseline scores were measured where a negative change from baseline indicates a decrease in the number of daily steps.

Outcome measures

Outcome measures
Measure
IPLEX™
n=13 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=20 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Daily Step Count
-140 daily step count
Standard Deviation 1222
-58 daily step count
Standard Deviation 1209

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

The peak activity index measures the number of steps walked in the 30 minutes of fastest walking that occurred in a 24 hour period. This was measured using a step activity monitor for 7 days at baseline and again at Week 24. Change from baseline scores were measured where a positive change from baseline indicates an improvement in the number of steps walked during the 30 minute period of fastest walking.

Outcome measures

Outcome measures
Measure
IPLEX™
n=13 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=20 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Peak Activity Index: Change From Baseline in Number of Steps Walked Per Minute During the 30 Minute Period of Fastest Walking
0.5 steps per minute (steps/min)
Standard Deviation 6.9
1.1 steps per minute (steps/min)
Standard Deviation 6.0

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

The sustained activity index measures the highest number of steps sustained over a continuous 20 minute period. This was measured using a step activity monitor for 7 days at baseline and again at Week 24. Change from baseline scores were measured where a positive change from baseline indicates an improvement in the number of steps walked over 20 minutes of activity.

Outcome measures

Outcome measures
Measure
IPLEX™
n=13 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=20 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Sustained Activity Index: Change From Baseline in the Highest Number of Steps Walked Per Minute Over 20 Minutes of Activity
-0.9 steps per minute (steps/min)
Standard Deviation 8.3
0.8 steps per minute (steps/min)
Standard Deviation 5.9

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

Change from baseline scores were measured where a negative change from baseline indicates less time spent inactive.

Outcome measures

Outcome measures
Measure
IPLEX™
n=13 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=20 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in the Percentage of Time That Participants Spent Inactive
-0.4 percentage of time
Standard Deviation 6.6
-0.0 percentage of time
Standard Deviation 5.2

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

Participants were timed on their ability to climb up 4 stairs and timed separately to climb down 4 stairs at baseline and at week 24. The stairs were free-standing or the same flight of stairs was used at each assessment. Change from baseline scores were measured where a positive change from baseline indicates an improvement in the time taken for paticipants to ascend or descend 4 stairs.

Outcome measures

Outcome measures
Measure
IPLEX™
n=23 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=25 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Time Taken for Participants to Ascend and Descend 4 Stairs
Ascend 4 stairs
0.0 seconds
Standard Deviation 0.8
-0.5 seconds
Standard Deviation 1.2
Change From Baseline in Time Taken for Participants to Ascend and Descend 4 Stairs
Descend 4 stairs
-0.1 seconds
Standard Deviation 1.0
-0.5 seconds
Standard Deviation 1.5

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

Participants were timed on their ability to travel 30 feet on the same surface at each assessment at baseline and at Week 24. Change from baseline scores were measured where a positive change from baseline indicates an improvement in the time taken to travel 30 feet.

Outcome measures

Outcome measures
Measure
IPLEX™
n=24 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=27 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Time Taken to Traverse 30 Feet
0.2 seconds
Standard Deviation 1.3
-0.2 seconds
Standard Deviation 2.2

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

The Purdue Pegboard Test consists of a board with two sets of 25 holes, 4 concave cups, and a number of small metal pins. Participants were required to pick up the pins from a holder and place them in the holes as quickly as possible over 30 seconds with their dominant hand. The score was calculated as the number of pins placed into holes in 30 seconds and was measured at baseline and Week 24. Change from baseline scores were measured where a positive change from baseline indicates an improvement in the number of pins placed in the board.

Outcome measures

Outcome measures
Measure
IPLEX™
n=25 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=29 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Purdue Pegboard Test Scores
-0.2 number of pins
Standard Deviation 2.4
0.3 number of pins
Standard Deviation 1.5

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

FVC is the volume of air that can be forcibly exhaled from the lungs after taking the deepest breath possible, as measured by spirometry.

Outcome measures

Outcome measures
Measure
IPLEX™
n=23 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=28 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Forced Vital Capacity (FVC) Volume While Sitting or Lying Down
Sitting FVC
-0.1 litres
Standard Deviation 0.3
0.0 litres
Standard Deviation 0.5
Change From Baseline in Forced Vital Capacity (FVC) Volume While Sitting or Lying Down
Lying down FVC
-0.2 litres
Standard Deviation 0.4
-0.1 litres
Standard Deviation 0.3

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

FVC is the volume of air that can be forcibly exhaled from the lungs after taking the deepest breath possible, as measured by spirometry.

Outcome measures

Outcome measures
Measure
IPLEX™
n=22 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=27 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Forced Vital Capacity (FVC) Percent Predicted While Sitting or Lying Down
Sitting FVC (%)
0.0 Percentage (%) of FVC predicted
Standard Deviation 6.8
-2.3 Percentage (%) of FVC predicted
Standard Deviation 11.0
Change From Baseline in Forced Vital Capacity (FVC) Percent Predicted While Sitting or Lying Down
Lying Down FVC (%)
-3.8 Percentage (%) of FVC predicted
Standard Deviation 8.4
-3.2 Percentage (%) of FVC predicted
Standard Deviation 11.1

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

The MMT was used to assess muscle strength in the distal muscles and the proximal muscles. Distal muscles assessments included wrist extension, wrist flexion, ankle dorsiflexion and plantarflexion. Proximal muscle assessments included shoulder abduction, elbow extension, elbow flexion, hip extension, hip abduction, hip flexion, knee extension and knee flexion. In MMT, each muscle assessment was given a score of 0 to 5, where 0 indicated 'no contraction palpable' and 5 indicated 'normal strength'. The scores from each muscle were summed and the maximum overall score of all measured muscles was 140, the maximum distal score was 40 and the maximum proximal score was 80. Higher scores indicated higher muscle strength. Change from baseline scores were measured where a positive change from baseline indicates an improvement in muscle strength.

Outcome measures

Outcome measures
Measure
IPLEX™
n=24 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=29 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Manual Muscle Test (MMT) Scores
Overall Score
0.9 Score on a scale
Standard Deviation 7.0
-0.3 Score on a scale
Standard Deviation 4.0
Change From Baseline in Manual Muscle Test (MMT) Scores
Distal Muscles
-0.4 Score on a scale
Standard Deviation 3.0
0.0 Score on a scale
Standard Deviation 1.5
Change From Baseline in Manual Muscle Test (MMT) Scores
Proximal Muscles
1.0 Score on a scale
Standard Deviation 4.4
-0.3 Score on a scale
Standard Deviation 2.9

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Modified Per Protocol Population:

The Selective Reminding Test measures verbal learning and memory and involves remembering a verbal list of 12 words. Participants were required to recall the 12 words presented. Words that were missed on recall were presented again, and the process was repeated until all 12 words were correctly recalled. The total word list recall and delayed recall were calculated as T-scores. Raw scores were converted to T-score using available normative data. Change from baseline T-scores were measured where a positive change from baseline indicates improvement in performance.

Outcome measures

Outcome measures
Measure
IPLEX™
n=21 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=25 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Selective Reminding Test T-Scores (Total Word and Delayed Words)
Word List T-Score
4.3 T-score
Standard Deviation 7.4
2.9 T-score
Standard Deviation 8.9
Change From Baseline in Selective Reminding Test T-Scores (Total Word and Delayed Words)
Delayed Recall T-Score
-3.2 T-score
Standard Deviation 8.2
0.04 T-score
Standard Deviation 7.8

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Modified Per Protocol Population

The Selective Reminding Test measures verbal learning and memory and involves remembering a verbal list of 12 words. Participants were required to recall the 12 words presented. Words that were missed on recall were presented again, and the process is repeated until all 12 words were correctly recalled. The cued recall scores ranged from 0-11 and multiple choice recognition scores ranged from 0-12. Change from baseline scores were measured where a positive change from baseline indicates an improvement in verbal recall and memory.

Outcome measures

Outcome measures
Measure
IPLEX™
n=21 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=25 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Selective Reminding Test Raw Scores (Cued Recall and Recognition)
Cued Recall Raw Score
0.0 Score on a scale
Standard Deviation 0.9
-0.4 Score on a scale
Standard Deviation 0.9
Change From Baseline in Selective Reminding Test Raw Scores (Cued Recall and Recognition)
Recognition Raw Score
0.0 Score on a scale
Standard Deviation 0.4
0 Score on a scale
Standard Deviation 0.4

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Modified Per Protocol Population

The Rey Complex Figure Test (RCFT) assesses visuospatial construction ability and visual memory through four different tests: copy (copying a complex geometric figure), immediate recall of the figure (drawing figure from memory at 3 minutes), delayed recall (drawing figure at 30 minutes after initial copy), and recognition score (selecting individual parts of the figure from sketches provided). Copy performances are divided into 18 components with a maximum score of 2 each. The maximum score for each figure is 36.

Outcome measures

Outcome measures
Measure
IPLEX™
n=22 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=27 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Rey Complex Figure (RCF) Test Scores
Recognition T-Score
-1.5 Score on a scale
Standard Deviation 14.3
5.9 Score on a scale
Standard Deviation 12.7
Change From Baseline in Rey Complex Figure (RCF) Test Scores
Immediate Recall T-Score
7.5 Score on a scale
Standard Deviation 7.9
4.8 Score on a scale
Standard Deviation 11.4
Change From Baseline in Rey Complex Figure (RCF) Test Scores
Delayed Recall T-Score
5.2 Score on a scale
Standard Deviation 8.5
4.8 Score on a scale
Standard Deviation 11.7

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Intention to treat (ITT) population: all enrolled participants who had at least one dose of IPLEX™ or placebo and had at least one post-baseline efficacy assessment. Only participants with data available for analysis are reported.

The LNS test from the Welchsler Adult Intelligence Scale-III was used to assess working memory. The test required that participants recall, in order, numbers and letters presented in an unordered sequence. The number of items is 21. With each item being marked 0 if reported incorrectly or 1 if reported correctly, the maximum score is 21. Raw scores were converted into T-scores using available normative data. Change from baseline T-scores were measured where a positive change from baseline indicates improvement in performance.

Outcome measures

Outcome measures
Measure
IPLEX™
n=28 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=33 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Letter-Number Sequencing (LNS) Test Scores
1.18 Score on a scale
Standard Deviation 3.64
-0.36 Score on a scale
Standard Deviation 2.09

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Modified Per Protocol Population

The TMT assesses executive function, sequencing, mental flexibility, visual spanning speed and motor function. In TMT Part A, the participant had to draw lines in the correct order between 25 numbers randomly arranged on the page. In TMT Part B, the participant had to draw lines between 25 numbers and letters in alternating order (e.g., 1-A-2-B...etc). Times for Part A and Part B were used to derive T-scores which can range from a minimum of 0 and a maximum of 100. Raw scores were converted into T-scores using available normative data. Change from baseline T-scores were measured where a positive change from baseline indicates improvement in performance.

Outcome measures

Outcome measures
Measure
IPLEX™
n=22 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=27 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Trail Making Test (TMT) Scores
TMT Part A
2.2 T-score
Standard Deviation 10.2
-0.3 T-score
Standard Deviation 9.1
Change From Baseline in Trail Making Test (TMT) Scores
TMT Part B
4.0 T-score
Standard Deviation 7.1
-0.9 T-score
Standard Deviation 8.9

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Modified Per Protocol Population

The Stroop Color Word Test measures selective attention and cognitive flexibility. The test has three parts, the Word test (reading words), the Color test (naming the ink color in which words are displayed) and the Color-Word test (saying the ink color not reading the word). An interference score was calculated from the Color, Word and Color-Word scores and is an indication of how well a person can complete a task while disregarding interfering information. Raw scores were converted into T-scores using available normative data. Scores range from 0 to 100. Change from baseline T-scores were measured where a positive change from baseline indicates improvement in performance.

Outcome measures

Outcome measures
Measure
IPLEX™
n=22 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=25 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in the Stroop Color Word Test Scores
Color T-Score
2.0 T-score
Standard Deviation 4.1
0.9 T-score
Standard Deviation 5.5
Change From Baseline in the Stroop Color Word Test Scores
Word T-Score
-0.4 T-score
Standard Deviation 7.0
2.0 T-score
Standard Deviation 6.8
Change From Baseline in the Stroop Color Word Test Scores
Color-Word T-Score
1.3 T-score
Standard Deviation 4.6
1.0 T-score
Standard Deviation 7.3
Change From Baseline in the Stroop Color Word Test Scores
Interference T-Score
0.9 T-score
Standard Deviation 4.6
-0.2 T-score
Standard Deviation 7.5

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

BDI-II is a validated self-reported instrument of 21 questions which are each scored 0-3. Total scores range from 0-63, with higher score totals indicating more severe depression symptoms. {0-9: indicates minimal depression; 0-18: indicates mild depression; 19-29: indicates moderate depression; 30-63: indicates severe depression. Lower scores indicate no or minimal depression, with a maximum total score of 63.

Outcome measures

Outcome measures
Measure
IPLEX™
n=24 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=28 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline to Week 24 Scores on the Beck Depression Inventory II (BDI-II) Questionnaire
-1.63 Score on a scale
Standard Deviation 6.34
-0.14 Score on a scale
Standard Deviation 5.44

PRIMARY outcome

Timeframe: Baseline - Pre-dose and 30, 60, 90 and 120 minutes post glucose solution; Week 24 - Pre-dose and 30, 60, 90 and 120 minutes post glucose solution

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

Participants were administered 75 grams (g) glucose solution prior to administration of the first dose of IPlex™ and after administration of the last dose. A 2-hour oral glucose tolerance test (OGTT) was performed under fasted conditions.

Outcome measures

Outcome measures
Measure
IPLEX™
n=21 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=25 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Average Fasting Glucose Concentration in the Blood
-6.8 milligrams per deciliter (mg/dL)
Standard Deviation 9.5
0.2 milligrams per deciliter (mg/dL)
Standard Deviation 10.5

PRIMARY outcome

Timeframe: Baseline - Pre-dose and 30, 60, 90 and 120 minutes post glucose solution; Week 24 - Pre-dose and 30, 60, 90 and 120 minutes post glucose solution

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

Participants were administered 75 g glucose solution prior to administration of the first dose of IPLEX™ and after administration of the last dose. A 2-hour OGTT was performed under fasted conditions.

Outcome measures

Outcome measures
Measure
IPLEX™
n=21 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=25 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Average Fasting Insulin Concentration in the Blood
-5.7 micro units per milliliter (μU/mL)
Standard Deviation 7.7
0.7 micro units per milliliter (μU/mL)
Standard Deviation 8.8

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

The QUICKI is based on fasting glucose and insulin measurements and are calculated using the following equation: QUICKI = 1/\[ log(fasting glucose in mg/dL) + log (fasting insulin in uU/mL) \]

Outcome measures

Outcome measures
Measure
IPLEX™
n=21 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=25 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Qualitative Insulin Sensitivity Check Index (QUICKI)
0.05 Index
Standard Deviation 0.04
-0.01 Index
Standard Deviation 0.05

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

The ISI-Matsuda is based on the average glucose and insulin values obtained during the entire oral glucose tolerance test and are calculated using the following equation: ISI = 10,000 / √ \[ fasting glucose (mg/dL) x fasting insulin(uU/mL) x mean glucose x mean insulin \]

Outcome measures

Outcome measures
Measure
IPLEX™
n=17 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=23 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Insulin Sensitivity Index-Matsuda (ISI-Matsuda)
5.5 Index
Standard Deviation 3.2
-1.4 Index
Standard Deviation 3.6

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

A negative change from baseline indicates a decrease in total blood cholesterol level.

Outcome measures

Outcome measures
Measure
IPLEX™
n=25 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=26 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Total Blood Cholesterol Level
-7.9 mg/dL
Standard Deviation 20.4
-2.7 mg/dL
Standard Deviation 30.1

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

A positive change from baseline indicates an increase in total blood LDL level.

Outcome measures

Outcome measures
Measure
IPLEX™
n=24 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=23 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Total Blood Low-density Lipoproteins (LDL) Level
1.5 milligrams per milliliter (mg/mL)
Standard Deviation 18.2
5.0 milligrams per milliliter (mg/mL)
Standard Deviation 20.9

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

A negative change from baseline indicates a decrease in total blood HDL level.

Outcome measures

Outcome measures
Measure
IPLEX™
n=25 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=26 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Total Blood High-density Lipoproteins (HDL) Level
0.3 mg/dL
Standard Deviation 9.9
-3.0 mg/dL
Standard Deviation 7.5

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

A negative change from baseline indicates a decrease in total blood triglycerides level.

Outcome measures

Outcome measures
Measure
IPLEX™
n=25 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=26 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Total Blood Triglycerides Level
-54.8 mg/mL
Standard Deviation 87.6
-21.7 mg/mL
Standard Deviation 105.9

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

The GSFQ contains 6 questions that assess the frequency of certain GERD symptoms and their impact on daily life. Scores were converted and reported out of 100 with higher scores indicative of more frequent and intense GERD symptoms. Change from baseline scores were measured where a negative change from baseline indicates less frequent and intense GERD symptoms.

Outcome measures

Outcome measures
Measure
IPLEX™
n=25 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=29 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Gastro-esophageal Reflux Disease (GERD) Symptom Frequency Questionnaire (GSFQ) Scores
-6.4 Score on a scale
Standard Deviation 11.8
-0.5 Score on a scale
Standard Deviation 8.8

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

The GSRS-IBS has 13 questions aimed at identifying the frequency and intensity of IBS symptoms during the past week. Answers are given a score from 1 (no discomfort at all) to 7 (very severe discomfort). A total score was calculated and ranged from 0 to 78. A lower score indicates less discomfort from IBS symptoms. Change from baseline scores were measured where a positive change from baseline indicates increased discomfort from IBS symptoms.

Outcome measures

Outcome measures
Measure
IPLEX™
n=25 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=29 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS) Questionnaire Scores
-0.29 Score on a scale
Standard Deviation 0.63
-0.02 Score on a scale
Standard Deviation 0.83

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

The SDQ had 15 questions relating to the oral phase and pharyngeal phase of swallowing. Answers for 14 questions were assigned a number (0-3) based on a 4-point verbal scale (never, seldom, frequently, very frequently) and the last question was a yes or no question about respiratory infections. A higher score is indicative of greater swallowing issues with 44.5 as the highest possible score. A total score of ≥ 11 suggests impairment. Change from baseline scores were measured where a positive change from baseline indicates increased swallowing impairment.

Outcome measures

Outcome measures
Measure
IPLEX™
n=24 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=29 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Swallowing Disturbance Questionnaire (SDQ) Scores
0.29 Score on a scale
Standard Deviation 3.3
-0.34 Score on a scale
Standard Deviation 4.4

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

The SF-36 is a 36-item questionnaire that evaluates quality of life through physical and mental health across eight scales, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability. Change from baseline scores were measured where a positive change from baseline indicates an improvement in quality of life.

Outcome measures

Outcome measures
Measure
IPLEX™
n=25 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=29 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Short Form (36) (SF-36) Questionnaire Scores
Physical Health
1.4 Score on a scale
Standard Deviation 6.9
-0.5 Score on a scale
Standard Deviation 5.7
Change From Baseline in Short Form (36) (SF-36) Questionnaire Scores
Mental Health
1.2 Score on a scale
Standard Deviation 7.3
1.2 Score on a scale
Standard Deviation 9.1

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

The BPI contains 15 questions that assess the severity of pain and its impact or interference on functions of daily life. Pain severity was measured as the mean of 7 items of the questionnaire on an 11-point scale where 0 indicates no pain and 10 indicates the worst pain. A higher score indicates greater pain. Categories assessed include worst pain in 24 hours and average pain. Change from baseline scores were measured where a positive change from baseline indicates a worsening in pain.

Outcome measures

Outcome measures
Measure
IPLEX™
n=25 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=29 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Brief Pain Inventory (BPI) Questionnaire - Severity Scores
Average pain
-0.2 Score on a scale
Standard Deviation 2.4
0.6 Score on a scale
Standard Deviation 2.1
Change From Baseline in Brief Pain Inventory (BPI) Questionnaire - Severity Scores
Worst pain in 24 hours
0.0 Score on a scale
Standard Deviation 2.6
0.5 Score on a scale
Standard Deviation 2.7

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Per protocol (PP) population: all enrolled participants who were at least 80% compliant with study dosing, had no more than 21 days interruption in therapy at any one time, had efficacy assessments required at the Week 24 study visit, met all inclusion and exclusion criteria, and were not major protocol violators. Only participants with data available for analysis are reported.

The BPI contains 15 questions that assess the severity of pain and its impact or interference on functions of daily life. Pain interference is measured as the mean of 7 items on an 11-point scale where 0 indicates no interference and 10 indicates complete interference. A higher score indicates greater impairment due to pain. Change from baseline scores were measured where a positive change from baseline indicates a worsening of interference due to pain.

Outcome measures

Outcome measures
Measure
IPLEX™
n=23 Participants
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=26 Participants
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Change From Baseline in Brief Pain Inventory (BPI) Questionnaire - Interference Scores
0.0 Score on a scale
Standard Deviation 1.6
-0.5 Score on a scale
Standard Deviation 1.6

Adverse Events

IPLEX™

Serious events: 7 serious events
Other events: 31 other events
Deaths: 1 deaths

Placebo

Serious events: 6 serious events
Other events: 34 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
IPLEX™
n=34 participants at risk
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=35 participants at risk
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Cardiac disorders
Bundle Branch Block Left
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Parotitis
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Cardiac disorders
Chest Pain
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Cardiac disorders
Ventricular Dysfunction
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Fall
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
5.7%
2/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Headache
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Dyspnoea
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Respiratory Failure
8.8%
3/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Pneumonia Aspiration
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.

Other adverse events

Other adverse events
Measure
IPLEX™
n=34 participants at risk
Participants received 1.0 mg/kg IPLEX™ (rhIGF-I/rhIGFBP-3) via a subcutaneous injection once a day for 24 weeks.
Placebo
n=35 participants at risk
Participants received a matching placebo to IPLEX™ once a day via a subcutaneous injection for 24 weeks.
Psychiatric disorders
Staring
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Psychiatric disorders
Stress Symptoms
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Renal and urinary disorders
Pollakiuria
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Reproductive system and breast disorders
Batholin's Cyst
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Reproductive system and breast disorders
Breast Tenderness
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Reproductive system and breast disorders
Dysmenorrhoea
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Asthma
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Bronchitis
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Dyspnoea Exacerbated
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Nasal Congestion
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Respiratory Tract Congestion
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Rhinitis
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Burning Sensation
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Disturbance in Attention
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Dysphonia
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Hyporeflexia
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Sensory Loss
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Sinus Headache
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Somnolence
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Psychiatric disorders
Agitation
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Psychiatric disorders
Anxiety
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Ear and labyrinth disorders
Ear Pain
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Vision Blurred
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
5.7%
2/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Abdominal Pain
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
5.7%
2/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Consitpation
23.5%
8/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
5.7%
2/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Diarrhoea
17.6%
6/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
14.3%
5/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Gastroesophageal Reflux Disease
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Nausea
11.8%
4/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
8.6%
3/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Stomach Discomfort
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Vomiting
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
11.4%
4/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Asthenia
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Fatigue
11.8%
4/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
14.3%
5/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Injection Site Bruising
8.8%
3/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
22.9%
8/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Hyperhidrosis
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Oedema
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Oedema Peripheral
14.7%
5/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
5.7%
2/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Pyrexia
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Influenza
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
5.7%
2/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Sinusitis
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
8.6%
3/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Urinary Tract Infection
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Contusion
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
5.7%
2/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Excoriation
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Fall
20.6%
7/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
14.3%
5/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Joint Sprain
8.8%
3/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Psychiatric disorders
Panic Disorder
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Decreased Appetite
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Arthralgia
20.6%
7/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
5.7%
2/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Back Pain
17.6%
6/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
17.1%
6/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Joint Swelling
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Muscle Cramp
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Muscular Weakness
17.6%
6/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
5.7%
2/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Myalgia
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Neck Pain
11.8%
4/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Pain in Extremity
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
8.6%
3/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Balance Disorder
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Carpal Tunnel Syndrome
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Dizziness
14.7%
5/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
14.3%
5/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Headache
26.5%
9/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
8.6%
3/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Hypoaethesia
8.8%
3/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
5.7%
2/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Insomnia
11.8%
4/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Paraesthesia
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Psychiatric disorders
Depression
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
5.7%
2/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Psychiatric disorders
Irritability
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Reproductive system and breast disorders
Endometriosis
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Reproductive system and breast disorders
Ovarian Cyst
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Cough
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
14.3%
5/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Nasopharyngitis
11.8%
4/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
8.6%
3/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Pharyngolaryngeal Pain
8.8%
3/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
8.6%
3/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Alopecia
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Pruritus Generalized
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Rash
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
8.6%
3/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Rash Papular
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Injection Site Burning
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
11.4%
4/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Injection Site Erythema
35.3%
12/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
8.6%
3/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Injection Site Haemorrhage
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
5.7%
2/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Injection Site Pain
32.4%
11/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
7/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Injection Site Pruritus
20.6%
7/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Injection Site Swelling
5.9%
2/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Blood and lymphatic system disorders
Lymph Node Pain
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Blood and lymphatic system disorders
Lymphadenopathy
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Blood and lymphatic system disorders
Neutropenia
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Cardiac disorders
Chest Pain
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Cardiac disorders
Cyanosis
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Cardiac disorders
Palpitations
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Cardiac disorders
Tachycardia
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Cardiac disorders
Ventricular Extrasystoles
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Congenital, familial and genetic disorders
Epidermal Naevus
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Ear and labyrinth disorders
Ear Disorder
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Ear and labyrinth disorders
Ear Infection
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Ear and labyrinth disorders
Vertigo
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Endocrine disorders
Goitre
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Conjunctivitis
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Corneal Abrasion
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Eye Swelling
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Retinal Haemorrhage
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Visual Field Defect
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Abdominal Pain Upper
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Change of Bowel Habit
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Defaecation Urgency
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Dyspepsia
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Flatulence
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Gastroenteritis Viral
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Haematochezia
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Inguinal Hernia
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Irritable Bowel Syndrome
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Toothache
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Gastrointestinal Haemorrhage
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Energy Increased
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Gait Abnormal
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Influenza Like Illness
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Injection Site Induration
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Injection Site Urticaria
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Pain
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Rigors
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Cystitis
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Eye and Eyelid Infections
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Fungal Infection
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Hordeolum
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Pharyngitis Streptococcal
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Rhinitis
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Staphylococcal Infection
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Upper Respiratory Tract Infection
20.6%
7/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
17.1%
6/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Back Injury
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Foot Fracture
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Hand Fracture
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Joint Injury
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Laceration
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Limb Injury
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Mouth Injury
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Patella Fracture
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Road Traffic Accident
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Scratch
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Skin Laceration
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Alanine Aminotransferase Increased
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Aspartate Aminotransferase Increased
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Ejection Fraction Decreased
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Gamma-Glutamyltransferase Increased
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
High Density Lipoprotein Decreased
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Neutrophil Count Decreased
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Oestradiol Increased
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Platelet Count Decreased
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Transaminases Increased
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Weight Increased
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
White Blood Cell Count Decreased
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Hypercholesterolaemia
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Hyperkalaemia
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Hypoglycaemia
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Increased Appetite
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Bursitis
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Jaw Inflammation
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Muscle Fatigue
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Muscle Twitching
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Musculoskeletal Stiffness
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Pain in Jaw
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cyst
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm Skin
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Amnesia
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Sleep Apnoea Syndrome
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Snoring
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Upper Respiratory Tract Congestion
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Dermatitis Contact
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Hair Growth Abnormal
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Hyperkeratosis
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Nail Disorder
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Rash Macular
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Skin Discolouration
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Swelling Face
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Vascular disorders
Hypotension
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Vascular disorders
Periorbital Haematoma
0.00%
0/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
2.9%
1/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Pneumonia Aspiration
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Dyspnoea
2.9%
1/34 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/35 • 28 weeks
All-cause mortality and serious adverse events are reported for all participants enrolled/randomized in the study. Other adverse events are reported for all participants who received at least one dose of study drug.

Additional Information

Insmed Medical Information

Insmed

Phone: 1-844-446-7633

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place